Digital Health Monthly: Scientific Webinar Series
Redefining ALS Clinical Endpoints: Unlocking the Potential of Digital Health Technologies
Tuesday, October 14, 2025 @ 12 PM ET
Upcoming Digital Health Monthly:
Scientific Webinar Series
Accelerating DHT Research and Drug Development with Open-Source Big Data from Population Studies
Tuesday, December 3 @ 12 PM ET
Digital Health Monthly: Scientific Webinar Series
Sensor-based DHTs are shedding an illuminating light on how people function in their real-world environments. Drug developers, researchers, patients, and regulators are realizing the multifaceted value sensor-based DHTs can bring to clinical research.
As their adoption continues to grow, the ActiGraph team is excited to continue ‘Digital Health Monthly’, a monthly series of science-focused webinars to share the latest high-impact developments in clinical research from innovators in the digital health field. Each month, we feature brief data-driven presentations from clinical researchers, data scientists, and biostatisticians on a focused topic with dedicated time for audience Q&A. We believe that together, we can move the digital health technology field forward faster, and we are excited for this opportunity to facilitate important discussions on the latest research with members of the digital health community.
Despite extensive efforts, recent Amyotrophic Lateral Sclerosis (ALS) drug development has faced significant setbacks, with multiple late-stage clinical trials failing to meet the primary endpoint. These setbacks reflect the complex biology and heterogeneity of ALS, as well as challenges in trial design, patient selection, and biomarker development. They also highlight the limitations of traditional endpoints such as ALSFRS-R and survival, underscoring the need for more sensitive, objective, and comprehensive measures of disease progression and treatment response.
In this session of Digital Health Monthly, we will discuss how multidisciplinary stakeholders can collaboratively handle this challenge at hand. You’ll also learn about specific digital health technologies that can complement traditional outcome measures to provide more sensitive measures across multiple modalities, including physical function, sleep, respiratory function, speech, and cognitive performance. We’ll bring together multiple stakeholders to represent different perspectives on how to advance the adoption of digital endpoints in ALS clinical trials.
ALS remains a devastating and incurable neurodegenerative disease with an urgent need for effective treatments. Through collaborative efforts between industry stakeholders and rigorous evidence generation, we can reach consensus on standardized measures to ensure scientific credibility and real-world impact to help advance new treatments for ALS.
